ArticleJournal of translational medicine2026
DHX9 transcriptional upregulation and lactylation at K1024 fuels a glycolysis-histone lactylation loop in osteosarcoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundHistone lactylation, a novel posttranslational modification driven by glycolytic lactate, has emerged as a key regulator of tumorigenesis. However, its role in osteosarcoma (OS) progression and the underlying metabolic‒epigenetic crosstalk remain poorly understood.
methodsUsing immunohistochemistry, molecular biology, and functional assays in vitro and in vivo, we investigated lactylation levels, DHX9 regulation, Lactylation and glycolytic activity in osteosarcoma models. Techniques included CUT&Tag, LC-MS/MS, site-directed mutagenesis, and xenograft studies.
resultsHere, we show global lactylation levels were significantly elevated in OS tissues compared with paracancerous controls. Glycolysis inhibition suppressed H3K9la and impeded OS malignancy. CUT&Tag identified H3K9la enrichment at the DHX9 promoter. DHX9 knockdown inhibited proliferation, migration, and invasion (in vitro) and tumor growth (in vivo), whereas DHX9 overexpression had the opposite effects. LC‒MS/MS revealed K1024 as a functional lactylation site on DHX9-K1024R mutation (lactylation-deficient) disrupted a feedforward loop: (1) reduced PKM2/LDHA expression → impaired glycolysis → decreased H3K9la; and (2) suppressed malignant phenotypes. Conversely, DHX9-K1024T (lactylation mimetic) partially rescued glycolytic enzyme expression and H3K9la levels.
conclusionWe elucidated a self-amplifying H3K9la-DHX9-K1024la-glycolysis circuit that drives OS progression. DHX9 lactylation at K1024 serves as a critical metabolic‒epigenetic interface, suggesting that K1024 lactylation may represent a potential therapeutic target, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.